Aequim Alternative Investments LP - THERAVANCE BIOPHARMA INC ownership

Quarter-by-quarter ownership
Aequim Alternative Investments LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$13,814,000
+4.9%
15,000,000
+7.8%
0.42%
+21.9%
Q1 2022$13,173,000
-2.5%
13,920,0000.0%0.35%
-17.8%
Q4 2021$13,509,000
+4.6%
13,920,0000.0%0.42%
-15.3%
Q3 2021$12,909,000
+18.7%
13,920,000
+21.9%
0.50%
+6.9%
Q2 2021$10,878,000
+256.3%
11,420,000
+280.7%
0.47%
+136.5%
Q1 2021$3,053,000
+7.5%
3,000,0000.0%0.20%
-5.7%
Q4 2020$2,840,0003,000,0000.21%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2023
NameSharesValueWeighting ↓
LINDEN ADVISORS LP 71,957,000$88,374,0003.14%
Context Capital Management, LLC 3,500,000$4,288,0002.87%
Mohican Financial Management, LLC 1,000,000$1,250,0002.40%
Verition Fund Management LLC 8,000,000$9,835,0000.79%
ZAZOVE ASSOCIATES LLC 8,170,000$10,024,0000.51%
Baupost Group 30,000,000$37,125,0000.46%
WOLVERINE ASSET MANAGEMENT LLC 24,020,000$29,431,0000.33%
SSI INVESTMENT MANAGEMENT LLC 3,007,000$3,683,0000.31%
CSS LLC/IL 2,900,000$3,556,0000.17%
Rock Springs Capital Management LP 1,500,000$1,844,0000.08%
View complete list of THERAVANCE BIOPHARMA INC shareholders